These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9731502)

  • 1. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors.
    Hermans IF; Daish A; Yang J; Ritchie DS; Ronchese F
    Cancer Res; 1998 Sep; 58(17):3909-17. PubMed ID: 9731502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
    Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
    J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
    Marzo AL; Lake RA; Robinson BW; Scott B
    Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration.
    Janicki CN; Jenkinson SR; Williams NA; Morgan DJ
    Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells.
    Rawson P; Hermans IF; Huck SP; Roberts JM; Pircher H; Ronchese F
    Cancer Res; 2000 Aug; 60(16):4493-8. PubMed ID: 10969797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting of human p53-overexpressing tumor cells by an HLA A*0201-restricted murine T-cell receptor expressed in Jurkat T cells.
    Liu X; Peralta EA; Ellenhorn JD; Diamond DJ
    Cancer Res; 2000 Feb; 60(3):693-701. PubMed ID: 10676655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice.
    Shimizu Y; Guidotti LG; Fowler P; Chisari FV
    J Immunol; 1998 Nov; 161(9):4520-9. PubMed ID: 9794377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
    Margenthaler JA; Flye MW
    J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis--implications for tumor tolerance.
    Robinson BW; Scott BM; Lake RA; Stumbles PA; Nelson DJ; Fisher S; Marzo AL
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):811s-817s. PubMed ID: 11300477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation.
    Hermans IF; Ritchie DS; Daish A; Yang J; Kehry MR; Ronchese F
    J Immunol; 1999 Jul; 163(1):77-81. PubMed ID: 10384102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TCR transgenic CD8+ T cells activated in the presence of TGFbeta express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection.
    Kapp JA; Honjo K; Kapp LM; Xu Xy; Cozier A; Bucy RP
    Int Immunol; 2006 Nov; 18(11):1549-62. PubMed ID: 16966495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
    Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
    Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice.
    Abdel-Motal UM; Friedline R; Poligone B; Pogue-Caley RR; Frelinger JA; Tisch R
    Clin Immunol; 2001 Oct; 101(1):51-8. PubMed ID: 11580226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro generation of regulatory CD8+ T cells similar to those found in mice with anterior chamber-associated immune deviation.
    Kezuka T; Streilein JW
    Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1803-11. PubMed ID: 10845601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of CD8+CTL responses following gene gun immunization targeting the skin with intracutaneous injection of antigen-transduced dendritic cells.
    Gaffal E; Schweichel D; Tormo D; Steitz J; Lenz J; Basner-Tschakarjan E; Limmer A; Tüting T
    Eur J Cell Biol; 2007 Dec; 86(11-12):817-26. PubMed ID: 16928407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immunity from naive CD8+ T cells activated in vitro with MHC class I binding immunogenic peptides and IL-2 in the absence of specialized APCs.
    Hauser C; Zipprich F; Leblond I; Wirth S; Hügin AW
    J Immunol; 1999 Jul; 163(1):330-6. PubMed ID: 10384132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.